As of 12:15pm ET
| +0.07 / +6.09%|
Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company has a pipeline of therapeutic and aesthetic product development programs based on the first Food and Drug Administration approved cell-based product, LAVIV™ (azficel-T), in aesthetics, all of which are based on the autologous fibroblast cell. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. Fibrocell Science was founded on September 1, 2009 and is headquartered in Exton, PA.
|David M. Pernock||Chairman & Chief Executive Officer|
|Keith Alan Goldan||CFO, Treasurer & Senior Vice President|
|John Maslowski||Vice President-Scientific Affairs|
|Michael F. Marino||Secretary, Senior Vice President & General Counsel|
|Kimberly M. Smith||Controller|